PDL BioPharma — Q2 2016 Earnings Presentation
10 slides from PDL BioPharma's earnings presentation, Aug 4, 2016
Slide 1: Second Quarter 2016 Financial Results Conference Call
¢PDL BioPharma’ Second Quarter 2016 FINANCIAL RESULTS CONFERENCE CALL August 4, 2016
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS @@@ This presentation contains forward-looking statements, including PDL’s expectations with respect to its future royalty revenues, expenses, net income, and cash provided by operating activities. Each of these forward-looking statements involves risks and uncertainties.
Slide 3: Focused on Long-term Growth
Focused on Long-term Growth <3 Primary focus remains to increase long term value for our shareholders Have committed over $1.4 billion since embarking on this strategy in 2012 Have demonstrated ability to do a wide variety of customized deal structures ®Have become partner of choice to leading life
Slide 4: Equity Investment in Noden
Equity Investment in Noden <3 Equity investment completed with Noden Pharma DAC and an affiliate (Noden) on July ‘st. Investment is part of an acquisition of specialty pharma products. * Total commitment of up to $334 million from PDL and Noden —Includes $110MM to Novartis at close and $40MM to Node
Slide 5: Noden and Tekturna
Noden and Tekturna <3 @Noden ¢ Formed for the purpose of acquiring specialty pharma products. * Domiciled in Ireland. * CEO of Noden, Elie Farah — Was CEO for Merus Labs in acquisition and successful commercialization of several specialty pharma products. ¢ It will be an operating company with US an
Slide 6: Income Generating Transactions
17 Income Generating Transactions <3 13 Current Investments: Rovalby Acauisition Fauibvinvesinent Royalty Acauisition Senior Secured Royalty Acauisition ProductAcauisiton 1 ‘Revesin seb ns = Opus AcelRx RIAD $2,500,000 Up t0$324,000,000 $65,000,000 Up to$140,000,000 $40,000,000 $65,500,000 uly 2016
Slide 7: Dividend Program
Dividend Program <3 Five cent dividend paid during first and second quarters of 2016 Top priority is long term growth to enhance shareholder value We have made the decision to eliminate the PDL dividend program at this time * Cash flow to be invested in acquiring income generating assets which will
Slide 8: Second Quarter Ended June 30, 2016
Second Quarter Ended June 30, 2016 Overview 44¢ ‘Three Months Ended Six Months Ended June 30, June 30, 2016 2015 2016 2015 GAAP earings per share - Diluted $0.03 $0.47 $0.37 $0.97 Adjustments to Non-GAAP net income (as detailed below) 0.06 (0.03) 0.24 (0.06) Non-GAAP earnings per share - Diluted $0.
Slide 9: Second Quarter Ended June 30, 2016
Second Quarter Ended June 30, 2016 64 Overview Three Months Ended Six Months Ended June 30, June 30, (In thousands, except per share amounts) 2016. 2015 2016. 2015, Royalties from Queen et al. patents $ 14.232 $ 116.884 $ 135.687 _$ 244.694 Royalty rights - change in fair value (855) 12.216 (27,957)
Slide 10: Question and Answer Session
¢PDL BioPharma’ QUESTION AND ANSWER SESSION